Grants for Private Institutions Of Higher Education

The Go Outside Fund, provided by the Natural Resources Foundation of Wisconsin, aims to connect youth with outdoor, nature-based learning experiences. This grant program directly aligns with the foundation's mission by fostering an appreciation for natural resources and encouraging hands-on engagement with the environment among the younger generation in Wisconsin. The program's core objective is to facilitate access to outdoor activities for children, thereby promoting environmental literacy and a deeper connection to nature. The primary beneficiaries of this fund are pre-K through 12th-grade students in Wisconsin. Teachers and partner organizations can apply for funding to cover various costs that enable outdoor learning, such as field supplies, transportation, substitute teachers, or educator expenses. The impact goals are centered on increasing opportunities for children to learn in outdoor settings, fostering a sense of stewardship, and enriching their educational experiences through direct interaction with nature. The fund prioritizes grant applications that include a significant component of outdoor activity and directly engage children in outdoor, nature-based learning. While alignment with classroom learning and standards is encouraged, it is not a strict requirement, emphasizing the program's focus on experiential learning. Grants between $100 and $500 are available, supporting a wide range of smaller-scale, impactful projects that meet the eligibility criteria. Eligible applicants include public charities with approved 501(c)(3) status, governmental units, American Indian nations or tribal communities, and accredited schools, colleges, or universities. The program's theory of change posits that by removing financial barriers and supporting educators and organizations, more Wisconsin youth will have access to enriching outdoor experiences, leading to increased environmental awareness and appreciation. The expected outcome is a measurable increase in youth participation in nature-based learning, contributing to a more environmentally conscious and engaged generation. Projects must benefit Wisconsin students, and activities must take place six weeks or more after the application due date, ensuring planned and impactful engagement.

The Adams County Community Foundation is offering a competitive grant program up to $1,000 for nonprofit leadership development. This initiative aligns with the foundation's mission to strengthen the capacity and effectiveness of nonprofit organizations within Adams County. By investing in leadership development, the foundation aims to empower local nonprofits to more effectively carry out their missions and serve the community. The primary beneficiaries of this grant program are Adams County nonprofit executive directors and board members. The impact goal is to increase their knowledge and effectiveness in leadership roles. This includes participation in training opportunities focusing on strategic planning, reorganization, and leadership development for staff and board members. The foundation prioritizes activities that directly enhance a nonprofit's ability to achieve its objectives. Eligibility criteria stipulate that applicants must be in a paid or volunteer leadership position (Executive Director or a position leading to Executive Director or Board Chair) for a qualified 501(c)(3) charity. The program considers the financial need of both the organization and the individual. Eligible activities include college courses, certification programs, or professional conferences in finance, fundraising, human resources, or other relevant skills. Travel and lodging costs may also be covered. The expected outcomes of this grant program are sound and measurable, emphasizing tangible improvements in leadership capabilities and organizational effectiveness. While the specific measurable results are not detailed, the objective to "increase their knowledge and effectiveness" suggests that participants will gain practical skills and implement new strategies. The grant funds will be paid directly to the nonprofit organization, not to individuals, ensuring that the investment supports the institutional growth and sustainability of Adams County's vital nonprofit sector.

The Infrastructure Grants, part of the Pennsylvania Department of Agriculture's Resilient Food Systems Infrastructure Program, aim to enhance the middle of the food supply chain through improved aggregation points, food processing infrastructure, and storage facilities. This grant supports projects that upgrade equipment, facilitate transition to licensed spaces, and expand storage capacities to boost local food production. Priority is given to projects that benefit underserved and veteran farmers, and socially disadvantaged individuals. Funding is prioritized for needs such as food hubs, cooperative developments, and increased cold storage, especially in urban areas.

This grant provides financial support for capital projects in healthcare, higher education, and human services in North Carolina, including funding for critical service delivery vehicles.

Governor Greg Abbott and the Texas Division of Emergency Management (TDEM) have announced the opening of applications for the Department of Energy's (DOE) grant program aimed at enhancing the resilience of electric grids against disruptive events. The program is designed to allocate competitive grants to improve infrastructure and reduce the likelihood and impact of such events on the electrical grid. The grant supports weatherization, fire-resistant technologies, monitoring and control systems, vegetation management, adaptive protections, and advanced modeling technologies. This grant opportunity is now active with a closing deadline of June 28, 2024.

With this solicitation, OJJDP seeks to support the development and dissemination of translational tools and resources current knowledge about what works packaged in accessible, comprehensible, actionable form for use by everyday youth serving (nonresearcher) practitioners, and lay persons to effect and sustain positive change on key topics spanning the juvenile justice continuum in order to improve the juvenile justice system and prevent juvenile delinquency.

The FY24 PCRP Exploration Hypothesis Development Award supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more of the FY24 PCRP Overarching Challenges. This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. Results of studies conducted through this award may provide the scientific premise upon which a new hypothesis can be based or initial proof of principle of an innovative hypothesis, laying the groundwork for future avenues of scientific investigation. Presentation of preliminary data is inconsistent with the intent of this award mechanism and is therefore strongly discouraged. However, logical reasoning and a sound scientific rationale for the proposed work must be described. Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i, Full Application Submission Type, for more information. New for FY24: Clinical research is allowed. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities. Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. The funding instrument for awards made under the program announcement will be grants (31 USC 6304). The anticipated direct costs budgeted for the entire period of performance for an FY24 Exploration Hypothesis Development Award should not exceed $150,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $3.60M to fund approximately 15 Exploration Hypothesis Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030. Research Involving Animals: All research funded by the FY24 PCRP Exploration-Hypothesis Development Award involving new and ongoing research with animals must be reviewed and approved by the USAMRDC Office of Human and Animal Research Oversight (OHARO; previously the Human Research Protection Office), Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is not required. Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies. Refer to the General Application Instructions for additional information.

The Minnesota Pollution Control Agency (MPCA) is offering approximately $4.5 million in grants to support organics management projects aimed at reducing the amount of organic material sent to landfills or incinerators. This funding is intended for projects that enhance or establish collection, processing (through composting, anaerobic digestion, or feeding to animals), and education/outreach initiatives related to organics management. Eligible entities must serve or operate within Minnesota, and include not-for-profit organizations, businesses, institutions, political subdivisions (e.g., counties, cities), state agencies, and tribal governments. Applications are due by 4 p.m. Central Time on June 10, 2024.

This grant opportunity, offered by Sanofi, aims to address gaps and provide educational resources related to the diagnosis and treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). CIDP is a heterogeneous, immune-mediated neuropathy characterized by demyelination of motor and sensory nerves, leading to various clinical challenges. Sanofi seeks proposals for educational programs, particularly those that can effectively recap information from the 2024 Peripheral Nerve Society Annual Meeting and offer independent medical education (IME) activities. Programs should focus on key evidence-based data and offer recommendations to healthcare providers dealing with CIDP, particularly in areas such as treatment options, clinical challenges, and the role of complement therapeutics in CIDP care.

This grant provides funding for interdisciplinary research at U.S. higher education institutions and qualified non-profit organizations to advance the mathematical understanding of artificial intelligence and its applications.

This grant provides funding for researchers and conservation organizations in the U.S. to conduct studies that link scientific research on biodiversity with practical conservation efforts to protect ecosystems and species.

The DoD Peer Reviewed Cancer, Impact Award is a grant aimed at funding advanced research projects that can quickly translate promising findings into clinical applications, with the goal of making a significant, near-term impact on critical cancer issues and improving patient outcomes.

The Water Resources Preservation Grant Program, funded by the Upper Guadalupe River Authority (UGRA), provides cost-share funding to support the design and construction of stormwater management practices. These practices, referred to as Best Management Practices (BMPs), include Low Impact Development (LID), nature-based solutions, and Green Stormwater Infrastructure (GSI). The goal is to reduce, infiltrate, filter, and delay stormwater runoff, thus protecting the health of waterways in Kerr County. Eligible projects can apply for rebates that cover a portion of the costs associated with these practices, with the aim of reducing pollutants like Total Suspended Solids (TSS) and Bacteria by significant percentages. The program supports new constructions or retrofits, emphasizes distributed and centralized treatment methods, and requires adherence to specific design guidelines.

The Pennsylvania Department of Education (PDE), Bureau of Special Education is inviting applications from Local Education Agencies (LEAs) and Institutions of Higher Education (IHEs) to develop or expand experiential learning opportunities. The goal is to engage secondary and postsecondary students in learning about working with students with disabilities, aiming to inspire future special educators. These opportunities include structured activities, programs, or events guided by current educators. The grant aims to foster the establishment or expansion of such opportunities and increase interest in special education careers among secondary and postsecondary students.

This grant from Sanofi's Rare Blood Disorders Medical Affairs department focuses on medical education programs addressing Immune Thrombocytopenia (ITP). The grant aims to support independent medical education (IME) activities that recap highlights from EHA 2024 and ISTH 2024 conferences on ITP, emphasizing enduring programs, accredited or non-accredited IME activities, and digital or omnichannel formats. Proposals should address existing healthcare gaps in the treatment and management of ITP, improving clinician knowledge and patient outcomes. The maximum grant request is $150,000, with a focus on comprehensive interventions that address knowledge and performance gaps in ITP treatment. Proposals should cover target audience generation, learning objectives, educational methods, faculty recruitment, program evaluation, and budget planning.

Ladies/Gentlemen: The United States Agency for International Development (USAID) is seeking applications for a Leader with Associate (LWA) cooperative agreement from qualified entities to implement the Civic DEFENDERS program. Eligibility for this award is not restricted. USAID intends to make an award to the applicant who best meets the objectives of this funding opportunity based on the merit review criteria described in this NOFO subject to a risk assessment. Eligible parties interested in submitting an application are encouraged to read this NOFO thoroughly to understand the type of program sought, application submission requirements, and selection process. To be eligible for award, the applicant must provide all information as required in this NOFO and meet eligibility standards in Section C of this NOFO. This funding opportunity is posted on www.grants.gov, and may be amended. It is the responsibility of the applicant to regularly check the website to ensure they have the latest information pertaining to this notice of funding opportunity and to ensure that the NOFO has been received from the internet in its entirety. USAID bears no responsibility for data errors resulting from transmission or conversion process. If you have difficulty registering on www.grants.gov or accessing the NOFO, please contact the Grants.gov Helpdesk at 1-800-518-4726 or via email at support@grants.gov for technical assistance. USAID may not award to an applicant unless the applicant has complied with all applicable Unique Entity Identifier and System for Award Management (SAM) requirements detailed in Section D.6.g. The registration process may take many weeks to complete. Therefore, applicants are encouraged to begin registration early in the process. Please send any questions to the point(s) of contact identified in Section G. The deadline for questions is shown above. Responses to questions received prior to the deadline will be furnished to all potential applicants through an amendment to this notice posted to www.grants.gov. Issuance of this notice of funding opportunity does not constitute an award commitment on the part of the Government nor does it commit the Government to pay for any costs incurred in preparation or submission of comments/suggestions or an application. Applications are submitted at the risk of the applicant. All preparation and submission costs are at the applicants expense. Thank you for your interest in USAID programs. Sincerely, Mir Ershadullah Agreement Officer

This funding opportunity supports researchers and students conducting mycological studies on mushroom-forming fungi in the Pacific Northwest, covering expenses like lab work, equipment, and conference participation.

There are over 3,100 local jails and 80 Indian country jails in the United States with a combined population on any given day of over 660,000 people. While these facilities vary drastically in size and age, the leaders of these facilities have more in common than not. Large or small, rural, or urban, the vast majority face the same challenges: staffing, succession planning, training, culture, resource shortages, data analysis, health care, substance abuse disorders, mental illness, facility design and operations, and early identification of trends and emerging issues within their populations, to name a few. And while there are commonalities among the many, the responsibility to the public for the life, health, and safety of the people in their custody and their employees while administering a constitutionally run jail is considerable and common to all.The Institute for Jail Administration (IJA) provides training to personnel in positions of leadership within local or tribal organizations responsible for operating a jail or that have a nexus to jail operations. The IJA assists them as leaders within their organizations and equips them to manage essential aspects of administering a jail and prepares them for positions of greater responsibility.

The FY24 PCRP Data Science Award mechanism supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insight from large and/or complex sets of prostate cancer data. If successful, the studies will enable progress toward addressing one or more of the FY24 PCRP Overarching Challenges. It is expected that any resources, tools, or computational processes generated by this award will be openly shared with the prostate cancer research and patient community. This mechanism is intended to fund research built upon the logic, concepts, and methods of one or more of the following research areas as they pertain to prostate cancer: Computational biology Bioinformatics Artificial intelligence and machine learning Epidemiology Analysis of omics data Medical imaging Digital pathology Analysis of other clinically annotated datasetsApplications may combine diverse data types for integrative analysis to increase knowledge about prostate cancer with respect to the FY24 PCRP Overarching Challenges. Applications that propose to develop resources or tools that allow research, clinical care, and patient community access to standardized and harmonized datasets for real-time clinical care applications are of particular interest; however, this award must not be used to support the development of new datasets. Studies utilizing data derived from large patient studies that include long-term health records or repositories with well-annotated and high-quality biospecimens are encouraged.Key Features: Research Approach: Applications may propose development of a new data-science-driven tool or apply an existing tool or method to gather and analyze information from large datasets with the intent of advancing prostate cancer research and patient care relative to the FY24 PCRP Overarching Challenges. Inclusion of preliminary data to support the scientific rationale and feasibility of research approaches is strongly encouraged, but not required. Any preliminary data provided should be from the laboratory of the Principal Investigator(s) (PI[s]) or member(s) of the collaborating team. Applicants are encouraged to include plans for rigorous validation, benchmarking, comparisons, and/or evaluations to assess the quality or utility of the tools and/or approaches that will be used or developed under this award. Any datasets used in the study design must be from established, retrospective databases and be sufficient in size to provide appropriate analytical and statistical power. Prospective recruitment of human subjects and/or clinical trials is not allowed under this funding opportunity. Applicants are expected to provide documentation demonstrating access to the appropriate datasets and/or patient samples in numbers sufficient to achieve robust results. Impact: Applications are required to clearly communicate how the proposed quantitative and/or analytical approaches, processes, and/or systems will address and provide a solution to one or more of the FY24 PCRP Overarching Challenges. The potential impact of the research, both short- and long-term, should be clearly described, including how the anticipated outcomes or products are distinct from existing research efforts in this area and/or how they will significantly outperform current approaches in this area. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care. Data and Resource Sharing Plan: It is expected that any resources, tools, and computational processes that are developed under this award will be openly shared with the prostate cancer research and patient community. Plans must be provided for how additional data generated by future studies will be incorporated to further inform and refine the data science tools, processes, and/or methods generated and/or used in this study. Refer to the CDMRPs Policy on Data Resource Sharing located on the Electronic Biomedical Research Application Portal (eBRAP) Funding Opportunities Forms web page https://ebrap.org/eBRAP/public/Program.htm for more information about the CDMRPs expectations for making data and research resources publicly available.Partnering PI Option: The FY24 PCRP Data Science Award encourages applications that include meaningful and productive collaborations between investigators. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application; collaborations between data scientists and clinicians are highly encouraged. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project, including the Project Narrative, Statement of Work (SOW) and other required components. If recommended for funding, each PI will be named on separate awards to the recipient organization. Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/ nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Data Science Award should not exceed $1.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $11.2M to fund approximately seven Data Science Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The FY24 PCRP Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research. All applications for the FY24 PCRP Physician Research Award are to be written by the PI, with appropriate direction from the mentor(s).Key elements of this award mechanism are as follows: Principal Investigator: Physicians with clinical duties and/or responsibilities who, at the application submission deadline, are either in the last year of an accredited graduate medical education program as a resident or fellow or within 5 years of having initiated a faculty appointment (including Instructor positions) are eligible to apply. The PI must demonstrate a commitment to a career as a physician-scientist and investigator at the forefront of prostate cancer research and clinical practice; however, the PI is not required to have previous prostate cancer research experience. The award is intended to provide protection of the PIs time for prostate cancer research. Applications are strongly encouraged to demonstrate protection of at least 20% of the PIs time for prostate cancer research, which is not required to be exclusive to this award but can include effort dedicated to other prostate cancer research projects. Mentor(s): This award requires the involvement of at least one designated mentor with an established research program in prostate cancer, as evidenced by recent publications, active funding, and successful mentorship. In addition, the mentor(s) must demonstrate a commitment to advancing the PIs career in prostate cancer research. Research Approach: Proposed research ideas are required to address one or more of the FY24 PCRP Overarching Challenges. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. The inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the PI, mentor(s), or member(s) of the collaborating team. Additionally, required resources should be identified and supported through documentation. Research involving human subjects is permitted under this funding opportunity but is restricted to studies without clinical trials. Correlative studies associated with an existing clinical trial are particularly encouraged, provided they are determined to be no greater than minimal risk by the Institutional Review Board (IRB) of record and the USAMRDC Office of Human and Animal Research Oversight (OHARO), Office of Human Research Oversight. Researcher Development Plan: An individualized researcher development plan is required and should be prepared with appropriate guidance from the mentor(s). The researcher development plan should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PIs development as an independent prostate cancer physician-scientist. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PIs institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution. Impact: The proposed research must address and provide a solution to one or more of the FY24 PCRP Overarching Challenges and ultimately should have the potential to make a significant impact on the programs mission of eliminating death and suffering from prostate cancer and enhancing the well-being of Service Members and their Families, Veterans, and all the patients and caregivers who are experiencing the impact of the disease.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data that are derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html. While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP PRA Award should not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $4.80M to fund approximately four PCRP Physician Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.